DOCSLIB.ORG

Aicar, a Widely Used AMPK Activator with Important AMPK-Independent Effects: a Systematic Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aicar, a Widely Used AMPK Activator with Important AMPK-Independent Effects: a Systematic Review cells Review AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review Dora Višnji´c 1,2,*, Hrvoje Lali´c 1,2 , Vilma Dembitz 1,2 , Barbara Tomi´c 1,2 and Tomislav Smoljo 1,2 1 Laboratory of Cell Biology, Croatian Institute for Brain Research, University of Zagreb School of Medicine, 10000 Zagreb, Croatia; [email protected] (H.L.); [email protected] (V.D.); [email protected] (B.T.); [email protected] (T.S.) 2 Department of Physiology, University of Zagreb School of Medicine, 10000 Zagreb, Croatia * Correspondence: [email protected] Abstract: 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAr) has been one of the most com- monly used pharmacological modulators of AMPK activity. The majority of early studies on the role of AMPK, both in the physiological regulation of metabolism and in cancer pathogenesis, were based solely on the use of AICAr as an AMPK-activator. Even with more complex models of AMPK downregulation and knockout being introduced, AICAr remained a regular starting point for many studies focusing on AMPK biology. However, there is an increasing number of studies showing that numerous AICAr effects, previously attributed to AMPK activation, are in fact AMPK-independent. This review aims to give an overview of the present knowledge on AMPK-dependent and AMPK- independent effects of AICAr on metabolism, hypoxia, exercise, nucleotide synthesis, and cancer, calling for caution in the interpretation of AICAr-based studies in the context of understanding AMPK signaling pathway. Citation: Višnji´c,D.; Lali´c,H.; Dembitz, V.; Tomi´c,B.; Smoljo, T. Keywords: AICAr; AMPK; metabolism; acadesine; exercise; cell cycle; purine; pyrimidine; can- AICAr, a Widely Used AMPK cer; leukemia Activator with Important AMPK-Independent Effects: A Systematic Review. Cells 2021, 10, 1095. https://doi.org/10.3390/ 1. Introduction cells10051095 In 1995, 5-amino-4-imidazolecarboxamide (AICA) ribonucleoside or riboside was first proposed to be used as the activator of AMP-kinase (AMPK) in intact cells or, in other words, Academic Editor: Yury Ladilov to play the same role that phorbol esters had in dissecting signaling pathways regulated by protein kinase C [1]. The study by Corton et al. was based on previous work showing that Received: 15 March 2021 administration of the AICA riboside to intact cells causes AICA ribonucleotide or ribotide Accepted: 1 May 2021 Published: 4 May 2021 to accumulate inside the cell [2], and a study by Sullivan et al. [3] demonstrated that AICA ribotide mimicked the effect of AMP on allosteric activation of rat liver AMPK. Since then, the compound that has been widely used as an AMPK-agonist was an exogenous Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in dephosphorylated AICA riboside that should be properly abbreviated AICAr. However, in published maps and institutional affil- more than 1700 articles that can be retrieved from PubMed on AMPK and AICA riboside, iations. AICAr is often abbreviated as AICAR, although the AICAR acronym should be reserved for AICA ribotide or the phosphorylated form that is a physiological, endogenous precursor in de novo purine synthesis [4]. The nomenclature is additionally complicated because the other name used for the endogenous substance or AICAR is ZMP [5]. Moreover, the search of the literature reveals the common use of acadesine instead of AICAr [4,6–19]. Copyright: © 2021 by the authors. As shown in Figure1, AICAR or ZMP is an AMP analog. As a cell-permeable Licensee MDPI, Basel, Switzerland. This article is an open access article nucleotide, AICAr enters the cells through adenosine transporters [20] and becomes phos- distributed under the terms and phorylated by adenosine kinase into AICAR [21]. AICAR or ZMP activates AMPK but conditions of the Creative Commons it is 40- to 50- fold less potent than AMP in AMPK activation and accumulates in high Attribution (CC BY) license (https:// concentrations in the cytoplasm [1], so that it was always likely that AICAr may have creativecommons.org/licenses/by/ several AMPK-independent effects. Similar to AMP, AICAR binds to the γ subunit of 172 4.0/). AMPK, allosterically activates the enzyme, stimulates phosphorylation at Thr by liver Cells 2021, 10, 1095. https://doi.org/10.3390/cells10051095 https://www.mdpi.com/journal/cells Cells 2021Cells, 102021, x ,FOR10, 1095 PEER REVIEW 2 of 172 of 17 tissueskinase or cells B1 (LKB1),is to detect and the protects level of against pThr172 pThr AMPK172 bydephosphorylation Western blot in lysates [22,23 ].upon Therefore, AICAr treat- ment.the most common method to test for AICAr-mediated activation of AMPK in particular tissuesIn this or article, cells iswe to will detect give the a brief level overvi of pThrew172 ofAMPK the present by Western knowledge blot on in lysatesAMPK-dependent upon andAICAr AMPK-independent treatment. effects of AICAr. FigureFigure 1. 1.AICArAICAr structure structure and mechanism.mechanism. 2. AICAr,In thisMetabolism article, we and will Diabetes give a brief overview of the present knowledge on AMPK- dependentSince 1995, and AICAr AMPK-independent has been a valuable effects oftool AICAr. to identify metabolic pathways associated with2. AMPK AICAr, activation Metabolism in and various Diabetes tissues and cells in vivo and in vitro. In liver cells, AICAr was foundSince to 1995, inhibit AICAr fatty has acid been and a valuable cholesterol tool tosynthesis identify metabolic[24], to increase pathways fatty associated acid oxida- tionwith [25], AMPK and to activation inhibit gluconeogene in various tissuessis by and decreasing cells in vivo transcriptionand in vitro. of In PEPCK liver cells, [26]. In skeletalAICAr muscle was found cells, to AICAr inhibit fattywas acidfound and to cholesterol activate glycogen synthesis [phosphorylase24], to increase fatty and acidincrease glycogenolysisoxidation [25 ],[27], and stimulate to inhibit gluconeogenesis fatty acid oxidation by decreasing and glucose transcription uptake of [28],PEPCK and[26 inhibit]. proteinIn skeletal synthesis muscle [29]. cells, All AICAr of these was studies found to su activatepported glycogen the role phosphorylase of AMPK as and a central increase meta- bolicglycogenolysis hub of the cell [27 ],that stimulate is activated fatty acid whenever oxidation the and ratio glucose of AMP/ATP uptake [28 is], high and inhibitand which actsprotein to increase synthesis catabolic [29]. and All ofinhibit these anabolic studies supported processes the(Figure role of2). AMPK as a central metabolic hub of the cell that is activated whenever the ratio of AMP/ATP is high and which acts to increase catabolic and inhibit anabolic processes (Figure2). 2 Cells 2021, 10, x FOR PEERCells REVIEW2021, 10, 1095 3 of 17 3 of 17 Figure 2.FigureA schematic 2. A schematic presentation presentation of molecular of molecular mechanisms mech ofanisms AICAr of Akt/PKB, AICAr Akt/PKB, Akt/protein Akt/protein kinase B; ki- PDK1, 3- phosphoinositidenase B; PDK1, dependent 3-phosphoinositide protein kinase-1; dependent PI3K, phosphatidylinositol protein kinase-1; 3-kinase; PI3K, phosphatidylinositol PIP3, phosphatidylinositol 3-ki- (3,4,5)- trisphosphate;nase; PIP3, IRS, insulin phosphatidylinositol receptor substrate; (3,4,5)-trisphosphate; TSC1/2, tuberous sclerosis IRS, complex insulin 1receptor protein /substrate; tuberous sclerosisTSC1/2, complex tu- 2 protein; Rheb,berous Ras sclerosis homolog complex enriched 1 inprotein the brain; / tuberous mTOR, mechanisticsclerosis complex target of2 rapamycin;protein; Rheb, mTORC1, Ras homolog mTOR complex en- 1; mTORC2,riched mTOR in complex the brain; 2; Rictor,mTOR, rapamycin-insensitive mechanistic target of companion rapamycin; of mTOR; mTORC1, PRAS40, mTOR proline-rich complex Akt1; substrate 40; Raptor, regulatory-associatedmTORC2, mTOR complex protein of2; mTOR;Rictor, AMPK,rapamycin-in adenosinesensitive monophosphate companion (AMP)-activated of mTOR; PRAS40, protein proline- kinase; p53, tumor suppressorrich Akt substrate protein p53; 40; S6K1, Raptor, p70 S6regulatory-associ Kinase 1; OXPHOS,ated oxidative protein phosphorylation;of mTOR; AMPK, 4E-BP1, adenosine eukaryotic mono- translation initiationphosphate factor 4E binding (AMP)-activated protein 1; GLUT4, protei glucosen kinase; transporter p53, tumor 4. suppressor protein p53; S6K1, p70 S6 Ki- nase 1; OXPHOS, oxidative phosphorylation; 4E-BP1, eukaryotic translation initiation factor 4E binding protein 1; GLUT4,However, glucose investigators transporter soon4. realized that ZMP in millimolar concentrations could exert many other effects, including modulation of other AMP-sensitive enzymes, like However, investigatorsglycogen phosphorylase soon realized [ 30that], andZMP fructose-1-6-biphosphatase, in millimolar concentrations a rate-controlling could exert many enzyme in other effects, includinggluconeogenesis, modulation whichof other is likelyAMP-sensitive to explain enzymes, why the like effects glycogen of AICAr phosphorylase on gluconeogenesis [30], and fructose-1-6-biphosphatase,in the liver are AMPK-independent a rate-controlling [ 31enzyme]. The bestin gluconeogenesis, way to assess the which role is of likely AMPK in the to explain why theeffects effects of AICArof AICArin vivoon gluconeocould begenesis provided in the by AMPKliver are knockout AMPK-independent mice. As shown [31]. in Table1, The best way to assessdata obtainedthe role of by AMPK transgenic in the mice effects models of AICAr revealed in vivo that could AICAr-mediated
Load more

Recommended publications
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Forms of Hypoxanthine Or, Through Interconversions, Guanine Or Adenine
    826 GENETICS: GOTS AND GOLLUB PROC. N. A. S. Summary.-The ribonucleic acids of isolated thymus nuclei can be separated into two distinct fractions, one of which probably represents ribonucleic acid of the nu- cleolus. Studies of the incorporation of orotic acid-6-C"4 and adenosine-8-C'4 into these RNA fractions in vitro show great differences in their metabolic activity and different susceptibilities to an inhibitor of RNA synthesis, the "nucleolar" RNA being by far the more active. It is a pleasure to acknowledge our indebtedness to Mr. Rudolf Meudt for his careful and expert technical assistance. * This research was supported in part by a grant (RG-4919 M&G) from the United States Public Health Service. I V. G. Allfrey, A. E. Mirsky, and S. Osawa, Nature, 176, 1042, 1955. 2 V. G. Allfrey, A. E. Mirsky, and S. Osawa, J. Gen. Physiol., 40, 451, 1957. 3 R. Logan and J. N. Davidson, Biochim. et Biophys. Acta, 24, 196, 1957. 4 S. Osawa, K. Takata, and Y. Hotta (in press). 6 J. M. Webb, J. Biol. Chem., 221, 635, 1956. 6 M. Bessis, in Traite de cytologie sanguine (Paris: Masson & Cie, 1954), p. 83. J. N. Davidson and R. M. S. Smellie. Biochem. J.. 52, 594, 1952. SEQUENTIAL BLOCKADE IN ADENINE BIOSYNTHESIS BY GENETIC LOSS OF AN APPARENT BIFUNCTIONAL DEACYLASE* By JOSEPH S. GOTS AND EDITH G. GOLLUB DEPARTMENT OF MICROBIOLOGY, SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PENNSYLVANIA Communicated by D. Wright Wilson, July 3, 1957 Along the biosynthetic pathway to the purines of nucleic acids, inosinic acid occurs as a pivotal point in a bifurcation which leads to adenylic acid along one branch and to guanylic acid along the other: (B) r- Adenylic acid (AMP) (A) Inosinic acid (IMP) (C) L|_ * Guanylic acid (GMP) Bacterial mutations may result in genetic impairments at three locations with respect to the pivotal inosinic acid, thus yielding auxotrophs with three broad classes of nutritional response.
    [Show full text]
  • Methods, Compositions, and Formulations for Preventing Or Reducing Adverse Effects in a Patient
    (19) TZZ 59 ¥_T (11) EP 2 594 273 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 22.05.2013 Bulletin 2013/21 A61K 31/70 (2006.01) A61K 31/7056 (2006.01) A61K 31/7076 (2006.01) (21) Application number: 12180542.8 (22) Date of filing: 28.03.2006 (84) Designated Contracting States: (72) Inventor: Mangano, Dennis T. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Hillsborough, CA 94010 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Cole, William Gwyn et al avidity IP (30) Priority: 28.03.2005 US 666071 P Merlin House Falconry Court (62) Document number(s) of the earlier application(s) in Baker’s Lane accordance with Art. 76 EPC: Epping, Essex CM16 5DQ (GB) 06739900.6 / 1 863 497 Remarks: (71) Applicant: Pericor Therapeutics, Inc. This application was filed on 15-08-2012 as a New York, NY 10118 (US) divisional application to the application mentioned under INID code 62. (54) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient (57) The present invention provides methods, com- a patient with decreased left ventricular function, a patient positions, formulations, and kits related to acadesine, or with a prior myocardial infarction, a patient undergoing a prodrug, analog, or salt thereof, and/or a blood clotting non-vascular surgery, or a fetus during labor and deliv- inhibitor for preventing or reducing adverse side effects ery. in a patient. The type of patient that may benefit includes EP 2 594 273 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 594 273 A1 Description BACKGROUND OF THE INVENTION 5 [0001] Gruber (U.S.
    [Show full text]
  • A Fairy Chemical, Imidazole-4-Carboxamide, Is
    www.nature.com/scientificreports OPEN A Fairy Chemical, Imidazole-4- carboxamide, is Produced on a Novel Purine Metabolic Pathway in Received: 25 September 2018 Accepted: 14 May 2019 Rice Published: xx xx xxxx Hirohide Takemura1, Jae-Hoon Choi 2,3, Nobuo Matsuzaki1, Yuki Taniguchi2, Jing Wu3, Hirofumi Hirai2,3, Reiko Motohashi2,3, Tomohiro Asakawa4, Kazutada Ikeuchi5, Makoto Inai6, Toshiyuki Kan6 & Hirokazu Kawagishi1,2,3 Rings or arcs of fungus-regulated plant growth occurring on the foor of woodlands and grasslands are commonly called “fairy rings”. Fairy chemicals, 2-azahypoxanthine (AHX), imidazole-4-carboxamide (ICA), and 2-aza-8-oxohypoxanthine (AOH), are plant growth regulators involved in the phenomenon. The endogeny and biosynthetic pathways of AHX and AOH in plants have already been proven, however, those of ICA have remained unclear. We developed a high-sensitivity detection method for FCs including ICA and the endogenous ICA was detected in some plants for the frst time. The quantitative analysis of the endogenous level of ICA in rice and Arabidopsis were performed using 13C-double labeled ICA. In addition, the incorporation experiment and enzyme assay using the labeled compound into rice and partially purifed fraction of rice indicated that ICA is biosynthesized from 5-aminoimidazole-4- carboxamide (AICA), a metabolite on the purine metabolic pathway. The relationship between ICA and AHX was also discussed based on quantitative analysis and gene expression analysis. “Fairy rings” is a phenomenon in which fruiting bodies of higher fungi occur afer turfgrass grows and/or dies in the form of rings1. Tese diameters vary from a few centimeters to more than 15 meters and it is also known as a disease of turfgrass all over the world2,3.
    [Show full text]
  • The Therapeutic Targeting of Folate Receptor Alpha Positive Tumors
    Wayne State University Wayne State University Dissertations 1-1-2015 The Therapeutic Targeting Of Folate Receptor Alpha Positive Tumors Via Folate Receptor Selective Novel 5- And 6- Substituted Pyrrolo [2,3-D]pyrimidine Antifolates" Shermaine Kimberly Mitchell-Ryan Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Molecular Biology Commons, Oncology Commons, and the Pharmacology Commons Recommended Citation Mitchell-Ryan, Shermaine Kimberly, "The Therapeutic Targeting Of Folate Receptor Alpha Positive Tumors Via Folate Receptor Selective Novel 5- And 6- Substituted Pyrrolo [2,3-D]pyrimidine Antifolates"" (2015). Wayne State University Dissertations. Paper 1155. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. THE THERAPEUTIC TARGETING OF FOLATE RECPTOR ALPHA POSITIVE TUMORS VIA FOLATE RECEPTOR-SELECTIVE NOVEL 5-AND 6- SUBSTITUTED PYRROLO [2,3-D] PYRIMIDINE ANTIFOLATES by SHERMAINE KIMBERLY MITCHELL-RYAN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan In partial fulfilment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2015 Major: CANCER BIOLOGY Approved By: ________________________________________ Advisor Date ________________________________________ ________________________________________ ________________________________________ ________________________________________ DEDICATION This dissertation is dedicated to Seamus Isaiah Ryan, my sun (son), my world and my very reason to press forward and claim every reward life has to offer. My sojourn through this process would not have been possible without the love, support and encouragement of my husband, Paul Seamus Ryan. Thank you for your steadfast devotion, patience and understanding.
    [Show full text]
  • Taxonomic Variations in the Gut Microbiome of Gout Patients With
    Méndez‑Salazar et al. Mol Med (2021) 27:50 https://doi.org/10.1186/s10020‑021‑00311‑5 Molecular Medicine RESEARCH ARTICLE Open Access Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism Eder Orlando Méndez‑Salazar1,2†, Janitzia Vázquez‑Mellado3, Carlos S. Casimiro‑Soriguer4,5, Joaquin Dopazo4,5,6,7, Cankut Çubuk8, Yessica Zamudio‑Cuevas9, Adriana Francisco‑Balderas9, Karina Martínez‑Flores9, Javier Fernández‑Torres9, Carlos Lozada‑Pérez10, Carlos Pineda11, Austreberto Sánchez‑González12, Luis H. Silveira13, Ana I. Burguete‑García14, Citlalli Orbe‑Orihuela14, Alfredo Lagunas‑Martínez14, Alonso Vazquez‑Gomez15, Alberto López‑Reyes16, Berenice Palacios‑González1* and Gabriela Angélica Martínez‑Nava9† Abstract Objective: To evaluate the taxonomic composition of the gut microbiome in gout patients with and without tophi formation, and predict bacterial functions that might have an impact on urate metabolism. Methods: Hypervariable V3–V4 regions of the bacterial 16S rRNA gene from fecal samples of gout patients with and without tophi (n 33 and n 25, respectively) were sequenced and compared to fecal samples from 53 healthy controls. We explored= predictive =functional profles using bioinformatics in order to identify diferences in taxonomy and metabolic pathways. Results: We identifed a microbiome characterized by the lowest richness and a higher abundance of Phascolarc- tobacterium, Bacteroides, Akkermansia, and Ruminococcus_gnavus_group genera in patients with gout without tophi when compared to controls. The Proteobacteria phylum and the Escherichia-Shigella genus were more abundant in patients with tophaceous gout than in controls. Fold change analysis detected nine genera enriched in healthy controls compared to gout groups (Bifdobacterium, Butyricicoccus, Oscillobacter, Ruminococcaceae_UCG_010, Lach- nospiraceae_ND2007_group, Haemophilus, Ruminococcus_1, Clostridium_sensu_stricto_1, and Ruminococcaceae_ UGC_013).
    [Show full text]
  • Exercise Pills: at the Starting Line
    Review Exercise Pills: At the Starting Line 1,2 3, Shunchang Li and Ismail Laher * Sedentary lifestyles, limited physical exercise, and prolonged inactivity Trends undoubtedly increase chronic diseases, including obesity, type 2 diabetes, The concept of ‘exercise pills’ has great and cardiovascular diseases. It is widely acknowledged that exercise induces potential for use in patients having low exercise compliance or in those for a number of physiological adaptations that have beneficial effects in the pre- whom regular exercise is not feasible. vention and treatment of these chronic metabolic diseases. Unfortunately, Our increased understanding of the molecular targets of physical exercise exercise compliance is extremely low and often not possible. The development makes it possible to design agents that of exercise science and molecular techniques has increased our understanding mimic the physiological benefits of of the molecular pathways responsive to exercise. Knowledge of these molec- exercise. ular targets has led to the development of chemical interventions that can mimic Current candidate exercise pills can be the beneficial effects of exercise without requiring actual muscle activity. This divided into three categories: pharma- review focuses on the concept of ‘exercise pills’ and how they mimic the effects cological agonists (AICAR, GW501516, GSK4716, SR9009), hor- produced by physical exercise including oxidative fiber-type transformation, mones (MOTS-c, irisin), and phyto- mitochondrial biogenesis, increased fat oxidation, angiogenesis, and improve- chemicals [resveratrol and (–)-epicatechin]. ment of exercise capacity. We also review candidate exercise pills, and contrast the beneficial effects and molecular mechanisms between physical exercise The signaling pathways of currently and exercise pills. described exercise pills are outlined.
    [Show full text]
  • Differential Effects of Post-Weaning Diet and Maternal Obesity
    nutrients Article Differential Effects of Post-Weaning Diet and Maternal Obesity on Mouse Liver and Brain Metabolomes Sofiane Safi-Stibler 1,2,3 , Etienne A. Thévenot 4 , Luc Jouneau 1,2 ,Mélanie Jouin 1,2, Alexandre Seyer 5,6,Hélène Jammes 1,2, Delphine Rousseau-Ralliard 1,2 , 1,2,7, , 1,2, , Christine Baly * y and Anne Gabory * y 1 UVSQ, INRAE, BREED, Université Paris-Saclay, 78350 Jouy-en-Josas, France; sofiane.safi[email protected] (S.S.-S.); [email protected] (L.J.); [email protected] (M.J.); [email protected] (H.J.); [email protected] (D.R.-R.) 2 Ecole Nationale Vétérinaire d’Alfort, BREED, 94700 Maisons-Alfort, France 3 Collège Doctoral, Sorbonne Université, 75005 Paris, France 4 CEA, LIST, Laboratory for Data Sciences and Decision, MetaboHUB, 91191 Gif-Sur-Yvette, France; [email protected] 5 Profilomic SA, 92100 Boulogne-Billancourt, 75008 Paris, France; [email protected] 6 MedDay Pharmaceuticals, 75008 Paris, France 7 NBO, INRAE, Université Paris-Saclay, 78350 Jouy-en-Josas, France * Correspondence: [email protected] (C.B.); [email protected] (A.G.); Tel.: +33-13465-2348 (A.G.) These authors have contributed equally to this work. y Received: 17 April 2020; Accepted: 24 May 2020; Published: 28 May 2020 Abstract: Nutritional changes during developmental windows are of particular concern in offspring metabolic disease. Questions are emerging concerning the role of maternal weight changes before conception, particularly for weight loss, in the development of diet-related disorders. Understanding the physiological pathways affected by the maternal trajectories in the offspring is therefore essential, but a broad overview is still lacking.
    [Show full text]
  • Caracterización Proteómica De La Interacción Y La Inserción De Proteínas De Membrana
    TESIS DOCTORAL Valencia, Octubre 2019 Doctorado en Biomedicina y Biotecnología Caracterización proteómica de la interacción y la inserción de proteínas de membrana Dirigida por: Dr. Manuel Mateo Sánchez del Pino Dr. Luis Martínez Gil Doctorado en Biomedicina y Biotecnología Departamento de Bioquímica y Biología Molecular Facultad de Biología, Campus Burjassot Valencia, Octubre 2019 Caracterización proteómica de la interacción y la inserción de proteínas de membrana Memoria realizada por Dª Natalia Mara Vera Velasco para optar al Grado de Doctor por la Universitat de València Dirigida por: Dr. Manuel Mateo Sánchez del Pino Dr. Luis Martínez Gil OBJETIVOS • Objetivo 1 Estudio del interactoma asociado a la inserción de proteínas de membrana. • Objetivo 2 Estudio de las proteínas humanas incluidas en el virión del virus Nipah. 1 2 Objetivo 1 Estudio del interactoma asociado a la inserción de proteínas de membrana. 3 4 CONTENIDOS OBJETIVO 1 OBJETIVOS ................................................................................................................................ 1 ABREVIATURAS ....................................................................................................................... 7 INTRODUCCIÓN ....................................................................................................................... 9 I1.1 Componentes lipídicos ..................................................................................................... 12 I1.2 Componentes proteicos ...................................................................................................
    [Show full text]
  • Subtractive Proteomics to Identify Novel Drug Targets and Reverse
    www.nature.com/scientificreports OPEN Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development Received: 1 March 2018 Accepted: 17 May 2018 of chimeric vaccine against Published: xx xx xxxx Acinetobacter baumannii Vandana Solanki & Vishvanath Tiwari The emergence of drug-resistant Acinetobacter baumannii is the global health problem associated with high mortality and morbidity. Therefore it is high time to fnd a suitable therapeutics for this pathogen. In the present study, subtractive proteomics along with reverse vaccinology approaches were used to predict suitable therapeutics against A. baumannii. Using subtractive proteomics, we have identifed promiscuous antigenic membrane proteins that contain the virulence factors, resistance factors and essentiality factor for this pathogenic bacteria. Selected promiscuous targeted membrane proteins were used for the design of chimeric-subunit vaccine with the help of reverse vaccinology. Available best tools and servers were used for the identifcation of MHC class I, II and B cell epitopes. All selected epitopes were further shortlisted computationally to know their immunogenicity, antigenicity, allergenicity, conservancy and toxicity potentials. Immunogenic predicted promiscuous peptides used for the development of chimeric subunit vaccine with immune-modulating adjuvants, linkers, and PADRE (Pan HLA-DR epitopes) amino acid sequence. Designed vaccine construct V4 also interact with the MHC, and TLR4/MD2 complex as confrm by docking and molecular dynamics simulation studies. Therefore designed vaccine construct V4 can be developed to control the host-pathogen interaction or infection caused by A. baumannii. Acinetobacter baumannii, an ESKAPE pathogen, has gained the attention of medical fraternity worldwide due to its nosocomial infection in hospital setup mainly ICUs and emergence of multi-drug resistance mechanism in it1–6.
    [Show full text]
  • Www .Alfa.Com
    Bio 2013-14 Alfa Aesar North America Alfa Aesar Korea Uni-Onward (International Sales Headquarters) 101-3701, Lotte Castle President 3F-2 93 Wenhau 1st Rd, Sec 1, 26 Parkridge Road O-Dong Linkou Shiang 244, Taipei County Ward Hill, MA 01835 USA 467, Gongduk-Dong, Mapo-Gu Taiwan Tel: 1-800-343-0660 or 1-978-521-6300 Seoul, 121-805, Korea Tel: 886-2-2600-0611 Fax: 1-978-521-6350 Tel: +82-2-3140-6000 Fax: 886-2-2600-0654 Email: [email protected] Fax: +82-2-3140-6002 Email: [email protected] Email: [email protected] Alfa Aesar United Kingdom Echo Chemical Co. Ltd Shore Road Alfa Aesar India 16, Gongyeh Rd, Lu-Chu Li Port of Heysham Industrial Park (Johnson Matthey Chemicals India Toufen, 351, Miaoli Heysham LA3 2XY Pvt. Ltd.) Taiwan England Kandlakoya Village Tel: 866-37-629988 Bio Chemicals for Life Tel: 0800-801812 or +44 (0)1524 850506 Medchal Mandal Email: [email protected] www.alfa.com Fax: +44 (0)1524 850608 R R District Email: [email protected] Hyderabad - 501401 Andhra Pradesh, India Including: Alfa Aesar Germany Tel: +91 40 6730 1234 Postbox 11 07 65 Fax: +91 40 6730 1230 Amino Acids and Derivatives 76057 Karlsruhe Email: [email protected] Buffers Germany Tel: 800 4566 4566 or Distributed By: Click Chemistry Reagents +49 (0)721 84007 280 Electrophoresis Reagents Fax: +49 (0)721 84007 300 Hydrus Chemical Inc. Email: [email protected] Uchikanda 3-Chome, Chiyoda-Ku Signal Transduction Reagents Tokyo 101-0047 Western Blot and ELISA Reagents Alfa Aesar France Japan 2 allée d’Oslo Tel: 03(3258)5031 ...and much more 67300 Schiltigheim Fax: 03(3258)6535 France Email: [email protected] Tel: 0800 03 51 47 or +33 (0)3 8862 2690 Fax: 0800 10 20 67 or OOO “REAKOR” +33 (0)3 8862 6864 Nagorny Proezd, 7 Email: [email protected] 117 105 Moscow Russia Alfa Aesar China Tel: +7 495 640 3427 Room 1509 Fax: +7 495 640 3427 ext 6 CBD International Building Email: [email protected] No.
    [Show full text]
  • Pyrrolo[2,3-D]Pyrimidine Classical
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 12-21-2018 Pyrrolo[2,3-d]pyrimidine Classical Antifolates for Targeted Cancer Chemotherapy- Applications of Bioisosteric and Regioisomeric Substitutions for Improved Tumor-Selectivity and Potency Manasa Punaha Ravindra Follow this and additional works at: https://dsc.duq.edu/etd Part of the Medicinal Chemistry and Pharmaceutics Commons Recommended Citation Punaha Ravindra, M. (2018). Pyrrolo[2,3-d]pyrimidine Classical Antifolates for Targeted Cancer Chemotherapy- Applications of Bioisosteric and Regioisomeric Substitutions for Improved Tumor-Selectivity and Potency (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1747 This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. PYRROLO[2,3-d]PYRIMIDINE CLASSICAL ANTIFOLATES FOR TARGETED CANCER CHEMOTHERAPY- APPLICATIONS OF BIOISOSTERIC AND REGIOISOMERIC SUBSTITUTIONS FOR IMPROVED TUMOR-SELECTIVITY AND POTENCY A Dissertation Submitted to the Graduate School of Pharmaceutical Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Manasa Punaha Ravindra December 2018 Copyright by Manasa Punaha Ravindra 2018 PYRROLO[2,3-d]PYRIMIDINE CLASSICAL ANTIFOLATES FOR TARGETED CANCER CHEMOTHERAPY- APPLICATIONS OF BIOISOSTERIC AND REGIOISOMERIC SUBSTITUTIONS FOR IMPROVED TUMOR-SELECTIVITY AND POTENCY By Manasa Punaha Ravindra Approved August 28, 2018 _______________________________ ____________________________ Aleem Gangjee, Ph. D. Marc W. Harrold, Ph. D. Distinguished Professor of Medicinal Professor of Medicinal Chemistry Chemistry Graduate School of Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Duquesne University, Duquesne University (Committee member) (Committee Chair) _______________________ _______________________ Patrick T.
    [Show full text]